RSV – Talk Bio

Actionable Insights Powered by AI

Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges

Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination